REG - Oncimmune Hldngs PLC - Grant of Options and PDMR Dealing

Oncimmune HoldingsAnnouncement

22/12/2021 11:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211222:nRSV5053Wa&default-theme=true

RNS Number : 5053W  Oncimmune Holdings PLC  22 December 2021

22 December 2021

 

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Grant of Options and PDMR Dealing

 

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics
group, today announces that, as part of its management incentivisation scheme,
options ("Options") to subscribe for 135,109 ordinary shares of £0.01 each in
the Company ("Ordinary Shares") were granted on 22 December 2021 to Cameron
Barnard, Chief Business Officer.

 

Following this grant, Mr Barnard holds Options over a total of 135,109
Ordinary Shares, representing approximately 0.20 per cent of the Company's
issued share capital of 69,137,848. Other than the grant of the Options,
neither Mr Barnard nor any of his connected persons have any beneficial
interest in Ordinary Shares.

 

The Options have been granted under the Oncimmune LLC Stock Option Plan, have
an exercise price of £1.68, being the closing price of Ordinary Shares in
Oncimmune Holdings plc on 21 December 2021, and vest annually in five equal
parts from the date of grant until the fifth anniversary of the grant.

 

This announcement, including the notification below, is made in accordance
with the requirements of Article 19 of the UK Market Abuse Regulation.

 

Notification and public disclosure of transactions by person discharging
managerial responsibilities and persons closely associated with them.

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Mr Cameron Barnard

 2    Reason for the notification

 a)   Position/status                                              Chief Business Officer

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Oncimmune Holdings plc

 b)   LEI                                                          213800HCYIWT6YPI1I02

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of £0.01 each

      Identification code                                          ISIN: GB00BYQ94H38

 b)   Nature of the transaction                                    Grant of options

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     £1.68             135,109

 d)   Aggregated information                                       N/A - single transaction

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      22 December 2021

 f)   Place of the transaction                                     Outside a trading venue

 

 

For further information:

 

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

 

WG Partners (Joint Broker)

David Wilson, Nigel Barnes

+44 (0)20 3705 9321

 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com (mailto:Oncimmune@fticonsulting.com)

+44 (0)20 3727 1000

 

 

About Oncimmune

 

Oncimmune is a leading immunodiagnostics developer, primarily focused on the
growing fields of immuno-oncology, autoimmune disease and infectious diseases.
Oncimmune has a diversified and growing revenue both from its portfolio of
diagnostic products to detect early-stage cancer and its contract discovery
and development service business whose platform delivers actionable insights
into therapies to the Company's pharmaceutical and biotech partners.

 

Our understanding of the immune system enables us to harness its sophisticated
response to disease to detect cancer earlier and to support the development of
better therapies. The key to improving cancer survival is early detection and
better selection for therapy. As a company, we are driven by our passion to
improve cancer survival and to give people extra time.

 

Oncimmune's ImmunoINSIGHTS platform enables life science organisations to
optimise drug development and delivery, leading to more effectively targeted
and safer treatments for patients. Oncimmune's immunodiagnostic technology,
EarlyCDT, can detect and help identify cancer on average four years earlier
than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung,
targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000
tests already performed for patients worldwide and its use being supported by
peer reviewed data in over 12,000 patients, we are poised to become an
integral component of future lung cancer detection programmes, globally.

 

Oncimmune's diagnostic products business is located at its laboratory facility
in Nottingham, UK and its ImmunoINSIGHTS service business at its discovery
research centre in Dortmund, Germany. The ImmunoINSIGHTS business development
team are based in the US and Europe and Oncimmune is seeking to replicate the
Dortmund facility in the US in the medium term.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFEUFFEEFSESE